Covid-19Is Novavax, the Latecomer Covid Vaccine, Worth the Wait?
Novavax's vaccine is based on proteins rather than mRNA and has been used since early 2022 in other countries.
PharmaAnalysis: A New Era of Vaccines Leaves Old Questions About Prices Unanswered
Using novel vaccines wisely ? directing them to the people who need them at a price they can afford ?...
PharmaHow a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits
A vaccine against tuberculosis, the world?s deadliest infectious disease, has never been closer to reality, with the potential to save...
Covid-19Health Workers Warn Loosening Mask Advice in Hospitals Would Harm Patients and Providers
A CDC draft controversially concludes that N95 face masks are equivalent to looser, surgical face masks in certain settings.
PharmaIRA-mandated Free Vax Could Save Seniors More Than $230M
As of January 1, vaccines are now free under Medicare Part D, and include vaccines for Tdap and shingles.
PharmaA Technicality Could Keep RSV Shots From Kids in Need
The CDC is now assessing whether nirsevimab would be eligible for the Vaccines for Children program.
Covid-19FDA Experts Are Still Puzzled Over Who Should Get Which COVID Shots and When
Panel disagrees with FDA proposal that everyone get at least one shot a year, saying more information is needed.
PharmaWhat Older Americans Need to Know About Taking Paxlovid
Seek treatment with antiviral therapy, which remains effective against new COVID variants.
PharmaBernie Blasts 'Unacceptable Corporate Greed' As Moderna Mulls 4X Price Hike for COVID Vax
Quadrupling the price of COVID-19 vaccine would make it too expensive for millions of Americans, the Vermont Independent says.
Covid-19Medicare Keeps Spending More on COVID-19 Testing. Fraud and Overspending Are Partly Why.
Medicare's COVID-19 testing costs reached over $2 billion in 2022. The growing costs concern some experts, who say financial incentives...
Clinical CareFlu Patients at Risk of Developing Sepsis
Sepsis can develop as the result of any kind of infection, including influenza.
PayerPaxlovid has been free so far. Next year, sticker shock awaits.
The U.S. government has so far purchased 20 million courses of Paxlovid, priced at about $530 each.